These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2752257)

  • 1. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
    Labrie F; Dupont A; Bélanger A; Cusan L; Brochu M; Turina E; Pinault S; Lacourciere Y; Emond J
    Br J Urol; 1989 Jun; 63(6):634-8. PubMed ID: 2752257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
    Bezwoda WR
    Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
    J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
    Labrie F; Dupont A; Cusan L; Gomez J; Emond J; Monfette G
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):943-50. PubMed ID: 2285608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma.
    Drago JR; Santen RJ; Lipton A; Worgul TJ; Harvey HA; Boucher A; Manni A; Rohner TJ
    Cancer; 1984 Apr; 53(7):1447-50. PubMed ID: 6697289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal androgen blockade in relapsed prostate cancer.
    Geller J; Albert JD
    Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1127-31. PubMed ID: 2934257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
    Manni A; Santen RJ; Boucher A; Lipton A; Harvey H; Simmonds M; White D; Gordon R; Ronher T; Drago J
    Anticancer Res; 1985; 5(2):161-5. PubMed ID: 3888046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
    J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Pummer K
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Béland L; Cusan L; Lachance R
    Clin Invest Med; 1990 Oct; 13(5):275-8. PubMed ID: 2276222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
    Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
    Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
    Dowsett M; Shearer RJ; Ponder BA; Malone P; Jeffcoate SL
    Br J Cancer; 1988 Feb; 57(2):190-2. PubMed ID: 3358910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
    Kruit WH; Stoter G; Klijn JG
    Anticancer Drugs; 2004 Oct; 15(9):843-7. PubMed ID: 15457124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; Gordon R; Rohner T; Drago J; Wettlaufer J
    J Steroid Biochem; 1987; 27(1-3):551-6. PubMed ID: 3695494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.